Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target

The benefits of novel oral anticoagulants are hampered by bleeding. Since coagulation factor IX (fIX) lies upstream of fX in the coagulation cascade, and intermediate levels have been associated with reduced incidence of thrombotic events, we evaluated the viability of fIXa as an antithrombotic targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankrom, Wendy, Wood, Harold B., Xu, Jiayi, Geissler, Wayne, Bateman, Tom, Chatterjee, Manash S., Feng, Kung‐I, Metzger, Joseph M., Strapps, Walter R., Tadin‐Strapps, Marija, Seiffert, Dietmar, Andre, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777260/
https://www.ncbi.nlm.nih.gov/pubmed/26977298
http://dx.doi.org/10.1002/prp2.207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777260/
https://www.ncbi.nlm.nih.gov/pubmed/26977298
http://dx.doi.org/10.1002/prp2.207

Ejemplares similares